Silver Spring, Maryland, USA: The U.S. Food and Drug Administration, FDA, has approved the use of a potentially lifesaving foam on patients in a clinical trial at a Boston hospital. Called ResQFoam, it was created to quickly stop internal bleeding in trauma patients.
Doctors have developed an injectable foam that expands inside the body, and they hope it will be a lifesaver in the emergency room, ER.
“It’s remarkable and it’s very exciting for us,” Dr. David King, a trauma surgeon at Massachusetts General Hospital, said.
The product was developed by Dr. King and a team from Arsenal Medical in Watertown, Massachusetts. Now, the FDA says it can be used in a study of up to 40 patients at Mass General.
King said it will allow doctors “to intervene and temporarily stop bleeding patients essentially the moment they arrive in the emergency department.”
The foam starts as two liquids injected into the body through the belly button, then it expands in the abdomen.
“It wraps around injured tissues and injured organs and puts gentle pressure on them which temporarily slows or stops hemorrhage,” he explained.
As a surgeon in the U.S. Army Reserve Medical Corps, King knows how critical time is when it comes to blood loss. He has treated fellow soldiers on the battlefield and victims of trauma on the home front.
“When you’re suffering from internal bleeding, we don’t know how much time you have because no one can see what types of injuries you have on the inside,” King said.
He said he hopes ResQFoam will give many more patients a fighting chance.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.